Displaying drugs 14026 - 14050 of 15377 in total
Haptoglobulin (human)
Investigational
GIVI-MPC
GIVI-MPC is a therapy that uses human-induced pluripotent stem cell-derived myogenic progenitor cells.
Investigational
Human umbilical tissue derived cells
Investigational
CEQ508
CEQ508 is a Live Attenuated E. Coli Expressing Beta Catenin ShRNA currently being investigated to treat Familial Adenomatous Polyposis.
Investigational
pGM169/GL67A
Investigational
Engensis
Investigational
IR-901
Investigational
Lexanersen
Lexanersen is an antisense oligonucleotide under investigation for use as a disease-modifying therapy in Huntington's disease.
Investigational
OPC1
OPC1 is an oligodendrocyte progenitor cell therapy being investigated for the treatment of acute spinal cord injury.
Investigational
AP-101
AP-101 is a recombinant human antibody directed against human misfolded superoxide dismutase 1.
Investigational
OT-15
Investigational
ABO-201
Investigational
Human ciliary neurotrophic factor, recombinant (E. coli)
Investigational
Tonabacase
Investigational
C-Alpha-stx1
Investigational
Tabituximab barzuxetan yttrium Y-90
A version of tabituximab barzuxetan radiolabeled with yttrium-90.
Investigational
Yttrium Y-90 Labetuzumab
Investigational
Allogenic bone marrow-derived mesenchymal stem cells
Investigational
BHT-3034
BHT-3034 is a DNA plasmid vaccine immunotherapy under investigation for the treatment of myasthenia gravis.
Investigational
SIS-101-ADO
SIS-101-ADO is a siRNA therapeutic under investigation for the treatment of Autosomal Dominant Osteopetrosis Type 2 (ADO2).
Investigational
PBKR03
PBKR03 is a non-replicating recombinant adeno-associated virus serotype hu68 vector, containing a transgene encoding the human galactosylceramidase (GALC) enzyme.
Investigational
ATX-01
ATX-01 is an antimiR, a chemically modified antisense oligonucleotide, designed to target microRNA 23b (miR-23b).
Investigational
Gentulizumab
Investigational
Displaying drugs 14026 - 14050 of 15377 in total